SAN JOSE, Calif.,
April 18,
2024 /PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced the appointment of
Sanjay Juneja, MD to its Cancer
Business Advisory Board.
Anixa Chairman and CEO Dr. Amit
Kumar stated, "Dr. Juneja is an accomplished medical
oncologist who has earned status as a top media personality on
cancer prevention and treatment innovations. His influence has
earned him invitations to help shape healthcare policy, and, most
importantly, his public voice empowers cancer patients with
knowledge, support, and hope. We anticipate that Sanjay's rapidly
growing national profile will aid in educating the cancer community
about the novelty of our vaccines and therapeutics. His broad reach
will be beneficial to Anixa as we advance our programs, including
enrollment and site recruitment for our current and upcoming
clinical trials."
Dr. Sanjay Juneja is a
board-certified hematologist and medical oncologist currently
practicing in Baton Rouge,
Louisiana. He is the host of the internationally engaged
'Target: Cancer Podcast,' and carries over one-half million
followers through his media brand 'TheOncDoc.'
"I am looking forward to participating and helping Anixa advance
the novel cancer vaccines and therapeutics they are developing. I
am especially looking forward to helping the company educate the
cancer community of physisicans, researchers, and patients about
Anixa's landscape changing approach," Dr. Juneja stated.
Dr. Juneja served on the White House Leaders in Social Media
roundtable and has been featured by The Washington Post, CNBC, PBS,
and WebMD, among many others. He is an active international keynote
speaker on the importance of collaborative and democratized
education, and an advocate for health equity with policies on both
a federal and state level. Dr. Juneja is an editorial board member
for the peer-reviewed research journal AI in Precision Oncology,
and a contributor to Entrepreneur Magazine. In Louisiana, he was recognized as a winner of
Business Report's 2022 Forty under 40, and ranked among the Capital
Region's Top 500 Most Influential Leaders in 2023.
Anixa Biosciences' Cancer Business Advisory Board is an elite
group that includes members such as Karen
Knudsen, Ph.D., current CEO of the American Cancer Society;
Gary Reedy, previous CEO of the
American Cancer Society; Mike
Shepard, Ph.D., inventor of Herceptin; and many others. The
full membership and corresponding biographies can be found in the
About section of the Anixa website.
Visit Dr. Juneja at sjunejamd.com and @theoncdoc on social
media platforms.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR- T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes a novel
vaccine being developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
as well as a vaccine to prevent ovarian cancer. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on clinical development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10- Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-welcomes-celebrity-oncologist-dr-sanjay-juneja-to-its-cancer-business-advisory-board-302120306.html
SOURCE Anixa Biosciences, Inc.